International Conference on
Heart Congress, Vascular Biology & Surgeons Meeting

Guy H Fontaine has made 17 original contributions in the design and the use of the first cardiac pace makers in the early 60s. He has serendipitously identified ARVD during his contributions to antiarrhythmic surgery in the early 70s. He has developed the technique of Fulguration to replace surgery in the early 80s (technique used during 30 years in Paris). He as obtained the Nobel Prize in Cardiac Electrophysiology by Pr Pierre Rijlant foundation at the Académie Royale de Bruxelles in 1983. He has been one of the 216 individuals who have made a significant contribution to the study of cardiovascular disease since the 14th century, one of the 500 greatest geniuses of the 21th Century (USA Books), one of the 100 Life Time Achievement (UK Book). He has more than 900 publications including 201 chapters in books. He is the reviewer of 26 scientific journals both in basic and clinical science. He served as a member of the Editorial Board of Circulation for 5 years, after reviewing articles for this journal during decades. He has given 11 master lectures of 90 minutes each in inland China in 2014. He has recently developed new techniques of hypothermia for brain protection in OHCA and Stroke. This technique has been fortuitously used after resuscitation of his wife at home in June 2011 with absolutely no neurologic deficit despite 6 minutes of no flow. He has also invented a high-tech device which can be considered the ultimate in palliative care by preventing unexpectedly awaking after ordinary sleep. This device was mostly designed for major neurologic disorders. To know more about him introduce his full name on Google “Guy Hugues Fontaine”. His main lectures for the year 2016 have been in Cardiology and Neurology in: London, Dubai, Berlin, Baltimore, Philadelphia, Las Vegas, Tucson, Miami and Dubai again.

Cardiovascular disease, Cardiac Electrophysiology, Cardiology & Neurology

Dr Mahadeo has been actively involved in Medical Research since 1992 and is currently a tenured scientist, working as a principal investigator (PI) within the UCL Institute of Cardiovascular Science. Her main research interest are focused on elucidating the mechanisms controlling transcriptional regulation of tissue-specific gene expression and cell fate in normal tissues (during embryogenesis or in adults) and changes which contribute to disease initiation or progression [e.g. cancer, cardiovascular disease (CVD) and metabolic diseases e.g. obesity and type 2 diabetes]. The studies utilised the related homeobox transcription factors, Brn-3b/POU4F2 and Brn-3a/POU4F1, to show how complex regulatory effects can be mediated, depending on cell type specificity and/or growth conditions. Data from this research has been pivotal for establishing novel paradigms to explain how different transcription factors can drive similar or antagonistic effects on key cellular functions e.g. proliferation, survival/apoptosis or differentiation, depending on coexpression and interactions with other regulators such as the p53 tumour suppressor protein. More recently, novel roles for these regulators in the cardiovascular system and potential links to metabolic dysfunction have begun to identify increasing complexity for these regulators in controlling cell fate either during development or in disease.

Transcriptional regulation of tissue-specific gene expression, Cardiovascular disease, Metabolic diseases

She has studied and worked with progenitor cells from placenta, umbilical cord, and adipose tissue along with their applications in regenerative medicine and flow cytometry, with publications in the field, including research fellowships. She has published 2 books about flow cytometry, the Greek edition was published in 2010 and in 2013 the book was published from AABB Press USA (Bestseller) and was placed as student reference material in Stanford University library, USA.

Regenerative medicine applications, cellular standards.

Dipak Ramji received his BSc (Hons) degree (Biochemistry) and his PhD from University of Leeds. This was followed by post-doctoral research at the EMBL (Heidelberg) and IRBM (Rome) with fellowships from the Royal Society and the EU. He joined Cardiff University in 1992 and is currently a Reader at Cardiff School of Biosciences. His research is focused on understanding how the immune and inflammatory responses regulate macrophage processes in atherosclerosis with the goal of attaining deeper mechanistic insight and identifying preventative/therapeutic agents. He has published over 80 peer-reviewed papers, reviews and book chapters (h index = 30). He is an Editorial Board member of 16 international journals.

Atherosclerosis,therapeutic agents